CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
C225 (cetuximab)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00700440
NCT00700440Phase 2Completed
CompareCT.gov

Phase II Study of Cetuximab Combined With Intensity Modulated Radiotherapy (IMRT) and Concurrent Chemotherapy of Cisplatin in Nasopharyngeal Carcinoma

Sun Yat-sen University·interventional·Posted Jun 18, 2008·Updated Mar 26, 2010

In Brief

A Phase 2 clinical trial evaluating C225 (cetuximab) for Nasopharyngeal Carcinoma. Completed, enrolled 100 participants across 1 site.

Detailed Summary

This is an open, multicenter phase Ⅱ clinical trial on cetuximab (C225) combined with IMRT + concurrent chemotherapy of cisplatin in locoregionally advanced nasopharyngeal carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesChina
CollaboratorsCancer Institute and Hospital, Chinese Academy of Medical Sciences, Sichuan Cancer Hospital and Research Institute, Fujian Cancer Hospital, Fudan University, Cancer Hospital of Guizhou Province, First Affiliated Hospital of Guangxi Medical University, Central South University

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 18, 2008
Enrollment StartJul 1, 2008
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.0 years ago

Interventions

C225 (cetuximab)drug

one week before and then weekly during radiotherapy